ADPT
Adaptive Biotechnologies Corporation
A maker of tools that read the immune system's genetic code. Its FDA-authorized clonoSEQ test hunts for the tiny traces of cancer cells that can linger after treatment for blood cancers like multiple myeloma, helping doctors spot a possible relapse early. The company was founded in 2009 by brothers Harlan and Chad Robins, after Harlan's lab work at a Seattle research center cracked how to sequence T-cell receptors; Chad, a business guy who joked he couldn't tell a T-cell receptor from a T-bone steak, handled the company side.
CUSIP: 00650F109HealthcareUS5 holders
Total Value
$721.20M
Total Shares
34.35M
Net Share Change
-91.5K
Activity
4 selling
Investor
Value
Shares
Weight
Change
